Tesamorelin Research for Body Composition
An evidence-based overview of research examining Tesamorelin in the context of body composition. This page synthesizes findings from peer-reviewed literature.
Research Summary
Tesamorelin improves body composition by simultaneously reducing visceral fat and increasing lean body mass. Clinical trials show approximately 1.4 kg increase in lean mass alongside significant VAT reduction, reflecting the dual anabolic and lipolytic effects of restored GH pulsatility.
The body composition changes occur without significant effect on total body weight or subcutaneous fat, representing a recomposition rather than simple weight loss. This is particularly relevant for HIV patients who often have preserved or increased subcutaneous fat alongside visceral accumulation.
Long-term data confirm maintenance of improved body composition with continued treatment, though effects reverse upon discontinuation, indicating the need for ongoing therapy.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Body Composition
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Tesamorelin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.